CR20200415A - Dosage forms and methods for enantiomerically enriched or pure bupropion - Google Patents
Dosage forms and methods for enantiomerically enriched or pure bupropionInfo
- Publication number
- CR20200415A CR20200415A CR20200415A CR20200415A CR20200415A CR 20200415 A CR20200415 A CR 20200415A CR 20200415 A CR20200415 A CR 20200415A CR 20200415 A CR20200415 A CR 20200415A CR 20200415 A CR20200415 A CR 20200415A
- Authority
- CR
- Costa Rica
- Prior art keywords
- bupropion
- dosage forms
- enantiomerically enriched
- methods
- pure bupropion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
<p>En la presente descripción se describen formas de dosificación de (<em>S</em>)-bupropión enriquecido enantioméricamente o (<em>R</em>)-bupropión enriquecido enantioméricamente. El (<em>S</em>)-bupropión o (<em>R</em>)- bupropión puede estar enriquecido con deuterio o pueden tener una abundancia isotópica natural. Estas formas de dosificación pueden administrarse, con la alimentación o en 5 ayunas, para tratar una afección mencionada en la presente descripción, para lograr un cierto parámetro farmacocinético de un bupropión o un metabolito de un bupropión, y/o para mejorar los niveles plasmáticos de dextrometorfano.</p><p> In the present description dosage forms of (<em> S </em>) -enantiomerically enriched bupropion or (<em> R </em>) -enantiomerically enriched bupropion are described. The (<em> S </em>) -bupropion or (<em> R </em>) -bupropion can be enriched with deuterium or can have a natural isotopic abundance. These dosage forms can be administered, with food or on an empty stomach, to treat a condition mentioned in the present description, to achieve a certain pharmacokinetic parameter of a bupropion or a metabolite of a bupropion, and / or to improve plasma levels of dextromethorphan. </p>
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862634718P | 2018-02-23 | 2018-02-23 | |
| US201962794469P | 2019-01-18 | 2019-01-18 | |
| US201962809480P | 2019-02-22 | 2019-02-22 | |
| PCT/US2019/019445 WO2019165379A1 (en) | 2018-02-23 | 2019-02-25 | Dosage forms and methods for enantiomerically enriched or pure bupropion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20200415A true CR20200415A (en) | 2021-02-03 |
Family
ID=67688503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20200415A CR20200415A (en) | 2018-02-23 | 2019-02-25 | Dosage forms and methods for enantiomerically enriched or pure bupropion |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP3755312A4 (en) |
| JP (3) | JP2021513998A (en) |
| KR (3) | KR20230075531A (en) |
| CN (2) | CN112087999A (en) |
| AU (3) | AU2019223187B2 (en) |
| BR (1) | BR112020017179A2 (en) |
| CA (1) | CA3092076A1 (en) |
| CL (1) | CL2020002166A1 (en) |
| CR (1) | CR20200415A (en) |
| EC (1) | ECSP20060179A (en) |
| IL (2) | IL276871B2 (en) |
| MA (1) | MA51914A (en) |
| MX (2) | MX2020008704A (en) |
| MY (1) | MY202993A (en) |
| NI (1) | NI202000056A (en) |
| NZ (1) | NZ767378A (en) |
| PE (1) | PE20211752A1 (en) |
| SG (1) | SG11202008056SA (en) |
| WO (1) | WO2019165379A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20200415A (en) * | 2018-02-23 | 2021-02-03 | Axsome Therapeutics Inc | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11291639B2 (en) | 2018-09-20 | 2022-04-05 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11660273B2 (en) | 2018-09-20 | 2023-05-30 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11660274B2 (en) | 2018-09-20 | 2023-05-30 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| CR20220119A (en) * | 2019-09-20 | 2022-06-22 | Axsome Therapeutics Inc | DOSAGE FORMS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION |
| US12156914B2 (en) * | 2022-06-30 | 2024-12-03 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising bupropion and cysteine |
| US11717518B1 (en) | 2022-06-30 | 2023-08-08 | Antecip Bioventures Ii Llc | Bupropion dosage forms with reduced food and alcohol dosing effects |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2483499A (en) * | 1998-01-29 | 1999-08-16 | Sepracor, Inc. | Pharmaceutical uses of optically pure (+)-bupropion |
| US6337328B1 (en) * | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
| EP1575565B1 (en) * | 2003-08-08 | 2010-01-06 | Biovail Laboratories International Srl | Modified-release tablet of bupropion hydrochloride |
| WO2012118562A1 (en) * | 2011-03-02 | 2012-09-07 | Rhine Pharmaceuticals, Llc | Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations |
| US9198905B2 (en) * | 2013-11-05 | 2015-12-01 | Antecip Bioventures Ii Llc | Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects |
| US10080727B2 (en) * | 2013-11-05 | 2018-09-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US9474731B1 (en) * | 2013-11-05 | 2016-10-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| WO2015095713A1 (en) * | 2013-12-20 | 2015-06-25 | Deuterx, Llc | Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion |
| CR20200415A (en) * | 2018-02-23 | 2021-02-03 | Axsome Therapeutics Inc | Dosage forms and methods for enantiomerically enriched or pure bupropion |
-
2019
- 2019-02-25 CR CR20200415A patent/CR20200415A/en unknown
- 2019-02-25 IL IL276871A patent/IL276871B2/en unknown
- 2019-02-25 KR KR1020237017449A patent/KR20230075531A/en not_active Ceased
- 2019-02-25 CN CN201980026874.5A patent/CN112087999A/en active Pending
- 2019-02-25 PE PE2020001272A patent/PE20211752A1/en unknown
- 2019-02-25 MA MA051914A patent/MA51914A/en unknown
- 2019-02-25 AU AU2019223187A patent/AU2019223187B2/en active Active
- 2019-02-25 IL IL313368A patent/IL313368A/en unknown
- 2019-02-25 MY MYPI2020004315A patent/MY202993A/en unknown
- 2019-02-25 EP EP19756920.5A patent/EP3755312A4/en active Pending
- 2019-02-25 JP JP2020544420A patent/JP2021513998A/en active Pending
- 2019-02-25 MX MX2020008704A patent/MX2020008704A/en unknown
- 2019-02-25 KR KR1020207027256A patent/KR20210003091A/en not_active Ceased
- 2019-02-25 BR BR112020017179-4A patent/BR112020017179A2/en unknown
- 2019-02-25 KR KR1020247017593A patent/KR20240091043A/en active Pending
- 2019-02-25 SG SG11202008056SA patent/SG11202008056SA/en unknown
- 2019-02-25 CN CN202510967625.3A patent/CN120827545A/en active Pending
- 2019-02-25 CA CA3092076A patent/CA3092076A1/en active Pending
- 2019-02-25 WO PCT/US2019/019445 patent/WO2019165379A1/en not_active Ceased
- 2019-02-25 NZ NZ767378A patent/NZ767378A/en unknown
-
2020
- 2020-08-20 MX MX2023009281A patent/MX2023009281A/en unknown
- 2020-08-21 CL CL2020002166A patent/CL2020002166A1/en unknown
- 2020-08-21 NI NI202000056A patent/NI202000056A/en unknown
- 2020-09-23 EC ECSENADI202060179A patent/ECSP20060179A/en unknown
-
2022
- 2022-06-27 AU AU2022204521A patent/AU2022204521B2/en active Active
- 2022-08-04 JP JP2022124557A patent/JP2022153638A/en active Pending
-
2024
- 2024-03-15 JP JP2024041381A patent/JP2024075655A/en active Pending
- 2024-08-17 AU AU2024205858A patent/AU2024205858A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021513998A (en) | 2021-06-03 |
| SG11202008056SA (en) | 2020-09-29 |
| CN120827545A (en) | 2025-10-24 |
| AU2024205858A1 (en) | 2024-09-05 |
| EP3755312A1 (en) | 2020-12-30 |
| MX2023009281A (en) | 2023-08-17 |
| MA51914A (en) | 2020-12-30 |
| CA3092076A1 (en) | 2019-08-29 |
| IL276871B1 (en) | 2024-07-01 |
| AU2022204521B2 (en) | 2024-09-05 |
| IL276871B2 (en) | 2024-11-01 |
| EP3755312A4 (en) | 2022-03-16 |
| NI202000056A (en) | 2021-01-11 |
| KR20230075531A (en) | 2023-05-31 |
| JP2024075655A (en) | 2024-06-04 |
| JP2022153638A (en) | 2022-10-12 |
| IL313368A (en) | 2024-08-01 |
| KR20240091043A (en) | 2024-06-21 |
| BR112020017179A2 (en) | 2020-12-22 |
| KR20210003091A (en) | 2021-01-11 |
| MY202993A (en) | 2024-05-31 |
| AU2019223187A1 (en) | 2020-09-17 |
| NZ767378A (en) | 2024-03-22 |
| AU2022204521A1 (en) | 2022-07-21 |
| CN112087999A (en) | 2020-12-15 |
| IL276871A (en) | 2020-10-29 |
| MX2020008704A (en) | 2020-12-07 |
| CL2020002166A1 (en) | 2020-10-23 |
| PE20211752A1 (en) | 2021-09-06 |
| WO2019165379A1 (en) | 2019-08-29 |
| ECSP20060179A (en) | 2020-12-31 |
| AU2019223187B2 (en) | 2022-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20200415A (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| EA201290833A1 (en) | APPLICATION OF AMISULPRIDE AS ANTI-TRAFFIC MEANS | |
| MX367209B (en) | AN INTRAVENOUS COMPOSITION INCLUDING IBUPROFEN AND PARACETAMOL IN COMBINATION. | |
| NO20076446L (en) | Container with hollow mold | |
| WO2020061486A3 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| BR112015001640A2 (en) | Formulations and production methods of formulations for use in colonic evacuation | |
| MX359672B (en) | Methods for chronic pain management and treatment using hcg. | |
| PH12022550738A1 (en) | Dosages and uses of ornithine phenylacetate for treating hyperammonemia | |
| PH12022550378A1 (en) | Soft capsule containing tyndalized bacteria in film | |
| MX2009008813A (en) | PHARMACEUTICAL COMPOSITION CONTAINING FLOROGLUCINOL AND PARACETAMOL. | |
| CO2022003126A2 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| 刘欣 et al. | How to Face the Difficulty in Our Life | |
| UA120529U (en) | METHOD OF PRESERVATION OF KIDNEY FUNCTION IN PATIENTS WITH GHOST AND METABOLIC SYNDROME | |
| 강혜규 et al. | Current Issues and Tasks in Social Welfare Administration | |
| Hyun | A Study on the Negative Common Idiomatic Phrase with Four Syllables in Modern Chinese | |
| AR099330A1 (en) | USE OF PARICALCITOL IN THE TREATMENT OF INFLAMMATORY ANEMIA | |
| Eliseeva | Graphic Trends in New Russian Cinema | |
| UA93429U (en) | Method for improving efficacy of preventing cardiovascular complications in patients with osteoarthrosis | |
| Vourvahis | Lersivirine/methadone | |
| Yazici | Acetylcysteine/aripiprazole/risperidone | |
| AR091633A1 (en) | INJECTABLE ACETAMINOFEN SOLUTION FOR ADMINISTRATION VIA ESPINAL | |
| UA127468U (en) | METHOD OF IMPROVING LIVES OF NEWBORN LAMBES WITH USE OF "KARAFEST + OV" | |
| Абдуллоева | Peculiarities of usage of prefixal derivatives in Nizami Gandzhavi’s creation | |
| Келдиёров | The principle of presentation of tales and stories in Khusayn Khorazmi’s “Djavokhir-ul-A sror” | |
| Hanna | Afective disorders: 9 case reports |